Danaher sells equipment, supplies and services used to research treatments, manufacture medicines and diagnose patients. In its second quarter of fiscal 2026, ended June 26, it bought patient-monitoring specialist Masimo for $9.843 billion in cash, net of acquired cash. The purchase broadened Danaher’s hospital business and helped lift total debt to $26.6 billion. Improving customer demand and the acquired products now need to generate cash to support that larger financing burden.
Reporting basis: This analysis uses Danaher Corporation and its consolidated subsidiaries’ unaudited U.S. GAAP accounts. The information cutoff is July 21, 2026, including that day’s earnings release; subsequent developments are outside this assessment. “Second quarter” and “first half” remain separate throughout. Filing identification and exact comparison dates appear in the calculation notes.
Source: Danaher second-quarter 2026 Form 10-Q, consolidated statements, Notes 2 and 10, and Management’s Discussion and Analysis, pages 1–8, 16–19 and 30–32.
1. The profit rebound was much larger than the improvement in sales
The disappearance of last year’s impairment explains most of the earnings rebound. Sales improved, but the profit figures need that comparison explained before they can show how the operating business changed. Operating profit is what remains after product costs and operating expenses, before interest, other nonoperating items and income taxes. Net earnings include those remaining items. Diluted earnings per share (EPS) divide net earnings by the average share count, including potential shares from employee awards.
In the second quarter of 2025, Danaher reduced the recorded value of a trade name in its genomics consumables business. Management had decided to reorganize businesses and stop treating that name as an asset with an indefinite life. Weaker genomics demand, including at emerging biotechnology companies and two large customers, also contributed. The resulting $432 million pretax expense reduced operating profit without using cash in that quarter. There was no equivalent impairment in the second quarter of 2026.
| Consolidated results; US dollars in millions except EPS and margins | Second quarter 2025 | Second quarter 2026 | First half 2025 | First half 2026 |
|---|---|---|---|---|
| Revenue | 5,936 | 6,265 | 11,677 | 12,216 |
| Gross profit | 3,523 | 3,611 | 7,034 | 7,202 |
| Operating profit | 760 | 1,127 | 2,034 | 2,471 |
| Operating margin | 12.8% | 18.0% | 17.4% | 20.2% |
| Net earnings | 555 | 870 | 1,509 | 1,899 |
| Net margin, calculated | 9.3% | 13.9% | 12.9% | 15.5% |
| Diluted EPS, US dollars | 0.77 | 1.23 | 2.10 | 2.68 |
Source: Second-quarter 2026 Form 10-Q, consolidated earnings statement, page 2; Note 8, pages 14–15; operating-profit discussion, page 32.
Quarterly net earnings increased 56.8%, calculated from the reported dollar amounts. Yet the prior-year trade-name impairment reduced earnings by $328 million after tax, slightly more than the entire $315 million increase in reported net earnings. That does not mean the rest of the business stood still: the current quarter also absorbed Masimo acquisition expenses. It means the headline growth rate is a poor measure of the underlying improvement.
A focused comparison helps separate those effects. The table below removes the identified impairments from 2025 and the specified Masimo acquisition charges from 2026. It leaves amortization of purchased intangible assets, normal operating costs and the acquired business’s ongoing profit contribution in place.
| Selected-item calculation; US dollars in millions | Second quarter 2025 | Second quarter 2026 | First half 2025 | First half 2026 |
|---|---|---|---|---|
| Reported operating profit | 760 | 1,127 | 2,034 | 2,471 |
| Identified impairment add-back | 432 | 0 | 447 | 0 |
| Specified Masimo acquisition-charge add-back | 0 | 108 | 0 | 125 |
| Operating profit after these exclusions | 1,192 | 1,235 | 2,481 | 2,596 |
| Margin after these exclusions | 20.08% | 19.71% | 21.25% | 21.25% |
Calculation notes: These are our non-GAAP, pretax calculations, not Danaher’s adjusted operating-profit measure or a claim about recurring profit. The first-half 2025 exclusion includes the trade-name impairment and a $15 million facility impairment; their combined after-tax expense was $339 million. The 2026 exclusions combine transaction expenses, acquisition inventory revaluation and specified employee payments. The quarter’s $108 million charge comprises $46 million in cost of sales and $62 million in selling, general and administrative expenses; the first-half total is $46 million plus $79 million.
Source: Second-quarter 2026 Form 10-Q, Note 2, pages 7–8; Note 8, pages 14–15; cost and operating-expense discussion, pages 36–37.
The specified Masimo charges were $95 million after tax for the quarter and $110 million for the first half.
Source: July 21 earnings release, reconciliation footnote C, PDF page 4.
On this limited basis, operating profit improved, but the quarterly margin declined and the first-half margin was essentially unchanged. Danaher’s own quarterly margin explanation reaches a similar conclusion: the benefit from last year’s impairment was partly consumed by acquisition charges, the acquired business’s margin effect, and product mix and operating-cost effects.
The pressure begins before administrative expenses. Gross margin fell from 59.3% to 57.6% in the quarter. Danaher identified product mix and the acquisition inventory charge as the main causes. Buying inventory at an accounting value above its previous carrying cost raises the expense recognized when that inventory is sold. That temporary charge matters, but Danaher also reported pressure from the mix of products sold. Different products earn different margins, so higher total sales need not produce a higher gross margin.
Below operating profit, smaller investment losses and higher interest income helped earnings. Other expense fell to $3 million from $42 million; interest income rose to $61 million from $8 million. Interest expense also increased, to $107 million from $71 million. A higher effective tax rate, 19.3% versus 15.3%, absorbed part of the pretax improvement. Danaher therefore entered the acquisition integration period with improving sales, rather than a broad surge in operating margins.
Source: Second-quarter 2026 Form 10-Q, Notes 6–7, pages 13–14, and cost, interest and tax discussion, pages 36–39.
2. Customers are buying more supplies, but the recovery is uneven
Recurring purchases support Danaher’s sales base, while customer schedules still affect growth. A drugmaker needs filters and purification materials as it produces medicines. A diagnostic laboratory needs reagents as it runs tests. Those repeat purchases connect Danaher’s sales to customer activity after the original equipment has been installed.
Danaher classified $5.200 billion of quarterly revenue as recurring, up from $4.970 billion. That was 83.0% of total sales, compared with 83.7%. The category includes consumables, services and operating-type leases; it is broader than subscription revenue and does not mean every purchase is contractually guaranteed. Equipment and other nonrecurring sales supplied the remainder.
Source: Second-quarter 2026 Form 10-Q, Note 4, pages 9–10.
To compare existing businesses, Danaher removes currency effects and sales from businesses acquired within the preceding year, with an adjustment for divested product lines, and calls the result “core” sales growth. Quarterly core growth was 3.0%, versus reported growth of 5.5%; acquisitions and currency added approximately 1.5 and 1.0 percentage points, respectively. First-half core growth was 2.0%. These company-reported growth contributions are rounded and should not be treated as exact dollar bridges.
| Segment; US dollars in millions except growth and margins | Second quarter 2025 sales | Second quarter 2026 sales | Second quarter 2026 core growth | Second quarter 2025 operating margin | Second quarter 2026 operating margin |
|---|---|---|---|---|---|
| Biotechnology | 1,850 | 1,920 | 2.5% | 28.7% | 29.0% |
| Life Sciences | 1,777 | 1,879 | 5.5% | -13.4% | 13.0% |
| Diagnostics | 2,309 | 2,466 | 2.0% | 24.0% | 16.9% |
Source: Second-quarter 2026 Form 10-Q, segment discussion, pages 33–36. Segment margins are reported GAAP measures and include the impairment and acquisition effects discussed in this analysis.
Biotechnology’s first-half core growth was 4.5%, stronger than its second-quarter rate. Consumables demand improved, and equipment helped in the quarter, although equipment sales remained lower over the first half. Certain large commercial customers moved shipments out of the quarter. This is a specific timing explanation from management, not evidence that all delayed sales have already been recovered. Price increases contributed 1.5 percentage points to segment growth in both periods, so core growth should not be read as pure unit-volume growth.
The longer comparison shows a recovery from weakness rather than uninterrupted expansion. Biotechnology core sales declined 4.5% in 2024 and increased 6.5% in 2025. Life Sciences core sales declined 2.0% and 1.5%, respectively. Those are full-year comparisons, distinct from the quarterly figures above.
Source: Danaher 2025 Annual Report, Biotechnology and Life Sciences discussions, printed pages 40–42.
There is supporting industry evidence for a consumables-led recovery. Competitor Sartorius reported that its Bioprocess Solutions revenue grew 8.1% at constant currencies in the first quarter of 2026, with recurring demand stronger than equipment demand. That earlier-quarter result supports the direction of customer activity; differences in dates, portfolios and growth definitions prevent a direct market-share conclusion. Sartorius also introduced an automated cell-therapy production platform, illustrating that competition extends to helping customers simplify manufacturing, not just supplying individual components.
Source: Sartorius first-quarter 2026 results, April 23, 2026, business development and Bioprocess Solutions discussion.
Within Danaher, Life Sciences provided the fastest quarterly core growth. Filtration led, helped by demand for microelectronics and energy products. Instruments and life-science consumables also improved. Pharmaceutical and biotechnology demand strengthened during the first half, while academic and government customers improved modestly but remained subdued. The breadth is encouraging, although some strength came from industrial filtration rather than biomedical research alone.
Geography adds another qualification. Core sales in developed markets declined slightly in the quarter, while the company’s “high-growth markets” grew more than 10% and represented about 31% of sales. Biotechnology growth was led by China, while Diagnostics remained weak there. The evidence supports a broader product recovery, but not an equally strong recovery across customer groups or countries.
Source: Second-quarter 2026 Form 10-Q, business outlook, page 30; Biotechnology and Life Sciences discussions, pages 33–35.
3. Diagnostics growth has not yet restored its profitability
Diagnostics sales grew in the quarter, but acquisition charges and pressure on existing operations reduced profit. Higher clinical-testing demand more than offset weaker respiratory-testing demand in quarterly core sales. Acquisition charges, the acquired business’s margin effect, and product mix and operating costs nevertheless lowered profitability.
Diagnostics revenue increased to $2.466 billion from $2.309 billion in the quarter. Operating profit nevertheless fell to $416 million from $554 million. Masimo supplied most of the reported sales-growth contribution, while existing-business core growth was 2.0%. Over the first half, core sales declined 1.0% and operating profit fell from $1.272 billion to $1.090 billion.
Respiratory demand explains part of that contrast. Danaher reported a less severe respiratory season than a year earlier. Growth in non-respiratory molecular tests did not fully offset the decline in respiratory tests. Clinical laboratories, acute-care diagnostics and pathology supplied positive growth elsewhere in the segment.
Danaher introduced a measure excluding respiratory testing: Diagnostics core growth on that basis was 5.0% in the quarter and 4.0% in the first half. This helps show what other testing businesses are doing. Respiratory tests still produce actual sales and profit, however, so the broader segment result remains the relevant measure of total performance.
Pricing also weighed on the business. Diagnostics price reductions subtracted 1.5 percentage points from growth in both periods. China’s purchasing program and healthcare reimbursement changes were important causes, with sales promotions also contributing in the first half. The company said the year-over-year policy impact was moderating as comparisons moved beyond the changes that began in late 2024. A smaller comparative drag can help growth without restoring the earlier selling price.
The margin evidence shows why removing acquisition expenses is insufficient. Danaher attributed 4.40 percentage points of the quarter’s 7.10-point Diagnostics margin decline to specified Masimo acquisition charges. A further 1.05 points came from the incremental effect of acquired businesses. The remaining 1.65 points reflected product mix and operating-cost effects, net of higher core sales. Existing operations therefore also contributed to the decline.
Source: Second-quarter 2026 Form 10-Q, Diagnostics discussion and margin explanation, pages 35–36.
The business consequence is that patient-monitoring expansion arrives while the existing Diagnostics portfolio is still managing pricing and test-mix pressure. Clinical demand provides a useful base, but returning the segment to stronger profitability requires both acquisition integration and a better balance of sales within existing operations.
4. Masimo adds a new hospital business before its full benefits arrive
Masimo broadens Danaher’s acute-care offering, while the financing and integration costs arrive first. Its monitoring technology measures patients’ condition and uses sensors and monitors in healthcare settings. This complements Danaher’s diagnostic products by extending its role in decisions made around seriously ill patients.
The acquisition closed on June 10, leaving only a short contribution period before the June 26 balance sheet. Masimo had generated approximately $1.5 billion of revenue in 2025. Danaher paid $9.843 billion in cash, net of acquired cash, and included another $45 million of replacement employee equity awards attributable to pre-acquisition service in the purchase accounting. Those amounts are different from the transaction’s initially announced enterprise value.
Management’s stated purpose was to widen the product range and create additional sales and earnings opportunities. In its February announcement, Danaher targeted more than $125 million of annual cost savings and more than $50 million of annual additional revenue from combining the businesses by the fifth full year after closing. The proposed mechanisms were Danaher’s operating-improvement system and global reach. These are management targets, and additional revenue is not an equal amount of additional profit.
Sources: Second-quarter 2026 Form 10-Q, Note 2, pages 7–8; Danaher acquisition announcement, February 17, 2026, strategic rationale and expected combination benefits.
A full-quarter contribution should change the sales comparison more quickly than a five-year savings program changes costs. The filing’s pro forma figures estimate what combined results would have looked like with Masimo included from the beginning of the prior annual period. Quarterly pro forma revenue was $6.511 billion for 2026 versus $6.307 billion for 2025, a calculated increase of 3.2%. These figures include assumed financing and purchase accounting, and relocate or exclude specified transaction charges. They are a scope comparison, not a forecast or a clean measure of organic growth.
The initial allocation placed $4.960 billion into goodwill and $4.844 billion into identifiable intangible assets, principally technology, customer relationships and trade names. Goodwill represents the acquisition amount left after identifying the acquired net assets. The other intangibles represent specific purchased business resources whose accounting cost is generally recognized over time. Their value depends on customers continuing to use the products and on the business delivering future earnings.
Source: Second-quarter 2026 Form 10-Q, Note 2, acquisition allocation and pro forma information, pages 7–8.
Leica Biosystems also planned to acquire StatLab, a histology-products supplier with about $250 million of 2025 revenue and over 85% recurring revenue. Closing was expected by year-end, subject to conditions and approvals; no purchase price was disclosed.
Source: Danaher July 21, 2026 earnings release, pending StatLab acquisition, PDF page 5.
Together, these choices show a clear commercial direction: deepen the supplies and technology Danaher sells into clinical workflows. The main financial test is whether those added businesses generate cash after integration spending, ongoing investment and financing costs.
5. The larger balance sheet mostly reflects the purchase, not a surge in inventory demand
Masimo explains much of the increase in assets and liabilities. It would be misleading to interpret the enlarged inventory or intangible balances as if they came entirely from Danaher’s existing businesses.
| Consolidated financial position; US dollars in millions | December 31, 2025 | June 26, 2026 |
|---|---|---|
| Cash and equivalents | 4,615 | 4,348 |
| Net trade receivables | 3,913 | 3,965 |
| Inventory | 2,489 | 3,260 |
| Net property, plant and equipment | 5,531 | 5,825 |
| Goodwill | 43,151 | 47,414 |
| Other intangible assets, net | 17,817 | 21,358 |
| Total assets | 83,464 | 92,367 |
| Financing debt, current and long-term | 18,418 | 26,558 |
| Total liabilities, calculated | 30,923 | 39,775 |
| Total equity, including noncontrolling interests | 52,541 | 52,592 |
Source: Second-quarter 2026 Form 10-Q, balance sheet, page 1; Notes 2, 8 and 10.
Inventory rose $771 million, or 31.0%. Masimo brought $667 million of inventory at its acquisition-date value. Finished goods accounted for $526 million of the total balance-sheet increase, with work in process and raw materials also higher. Separately, the cash-flow statement shows that inventory absorbed $178 million in the first half. The acquisition-date balance and operating cash movement answer different questions and are not a complete bridge because currency, acquisition accounting and other changes also intervene.
Receivables increased only $52 million even though the acquisition brought $232 million of receivables. The operating cash-flow statement records a $137 million cash benefit from receivable changes. That means collections and related operating movements released cash; the closing balance alone would hide that benefit. The allowance for doubtful accounts—the amount set aside for invoices Danaher does not expect to collect—increased from $114 million to $121 million. Those balances alone do not show how much expense for expected credit losses entered the period’s earnings.
Property, plant and equipment increased $294 million. Danaher spent $506 million on additions, recorded $389 million of depreciation and acquired $355 million of property through Masimo. These items do not reconcile the entire movement without other changes. Management identifies capacity additions, replacement equipment, customer-leased instruments, buildings, product development and information technology as typical capital uses. It does not disclose a maintenance-versus-growth split.
Goodwill rose by $4.263 billion: the $4.960 billion purchase addition was partly offset by $697 million of currency translation and other changes. Net identifiable intangibles rose $3.541 billion, with the acquisition addition partly offset by $897 million of first-half amortization and other movements. Together, goodwill and net intangibles represented a calculated 74.5% of assets. That makes the future performance of purchased businesses central to the balance sheet.
Sources: Second-quarter 2026 Form 10-Q, balance sheet and cash-flow statement, pages 1 and 5; Notes 1–2 and 8; investing discussion, page 41.
Operating liabilities moved differently from borrowing. Trade payables slipped from $1.844 billion to $1.822 billion, while accrued expenses and other current liabilities fell $89 million. Other long-term liabilities increased $823 million. Long-term tax liabilities rose from approximately $3.0 billion to $3.9 billion. They include income taxes payable and deferred tax liabilities. Masimo’s purchase allocation included $1.088 billion of deferred tax liabilities, which record future tax consequences of differences between accounting values and tax values. These tax obligations are separate from financing debt.
Customer advances also helped finance operations. Contract liabilities rose from approximately $1.6 billion to $1.7 billion, reflecting advance payments and the acquisition, partly offset by revenue already earned. Danaher recognized $804 million of first-half revenue from the opening contract-liability balance. These customers paid before Danaher completed the promised work, unlike customers whose unpaid invoices appear in receivables. The enlarged balance sheet therefore combines acquired resources, financing obligations and ordinary customer-payment timing.
Source: Second-quarter 2026 Form 10-Q, Notes 1–2 and 4, pages 7–11.
6. Cash generation covered ordinary investment and distributions, but not Masimo
Operating cash generation remained strong; the acquisition required substantial borrowing. First-half operating cash flow increased 8.3%, much less than the 25.8% increase in net earnings because last year’s impairment had reduced profit without consuming operating cash.
| First-half cash allocation; US dollars in millions | First half 2025 | First half 2026 |
|---|---|---|
| Operating cash flow | 2,637 | 2,856 |
| Capital spending, positive cash outlay | 493 | 506 |
| Free cash flow after gross capital spending, calculated | 2,144 | 2,350 |
| Cash dividends paid | 423 | 509 |
| Cash share repurchases paid | 1,078 | 894 |
| Remainder after these distributions, calculated | 643 | 947 |
| Cash acquisition spending, net of acquired cash | 0 | 9,843 |
Calculation notes: Free cash flow here equals operating cash flow less gross payments for property, plant and equipment. Asset-sale receipts are excluded. Danaher’s published definition deducts net capital spending; the definitions coincide in 2026 because property-sale proceeds were zero, but differ by $10 million in the 2025 comparison. The remainder precedes investments, debt transactions, excise taxes on repurchases and other financing flows.
Sources: Second-quarter 2026 Form 10-Q, cash-flow statement, page 5; July 21 earnings release, free-cash-flow reconciliation and definition.
The profit-to-cash bridge explains the difference. First-half net earnings of $1.899 billion included $1.286 billion of depreciation and intangible amortization. Those expenses spread earlier asset costs across time and did not require the same cash payment in this period. Other listed noncash adjustments added $281 million, including stock compensation, investment losses and the acquired-inventory adjustment.
Changes in operating assets and liabilities then used a net $610 million. Receivables released $137 million, but inventory used $178 million and payables used $79 million. Collecting invoices helped cash, while stocking products and settling supplier obligations used it. Other assets released $81 million, while accrued expenses and other liabilities used $571 million. Together, those last two categories used $490 million, compared with $573 million a year earlier. Management attributed most of that $83 million improvement to the timing of employee obligations, customer funding, indirect taxes and accrued expenses.
Compared with 2025, the $390 million earnings increase was offset by $359 million less in listed noncash adjustments. Receivables, inventories and payables together used $105 million less cash. Adding that improvement and the $83 million improvement described above reconciles the $219 million increase in operating cash flow. Payment timing therefore contributed materially to stronger cash generation alongside earnings.
Source: Second-quarter 2026 Form 10-Q, cash-flow statement, page 5, and operating-cash discussion, pages 40–41.
The spending comparison also matters. Diagnostics capital spending rose to $308 million from $240 million, while Biotechnology and Life Sciences spending declined to $130 million and $65 million, respectively. Total spending increased only $13 million. Research and development expense rose to $799 million from $782 million, so the company continued funding product work while buying additional technology through Masimo.
The cash balance reconciles fully: $4.615 billion at the start, plus $2.856 billion from operations, minus $10.396 billion used in investing, plus $7.319 billion from financing, minus $46 million from exchange-rate changes, equals $4.348 billion. Net borrowing cash inflows were $8.794 billion. Cash generation was sufficient for capital spending, dividends and repurchases, but retaining those distributions left only a small portion of Masimo’s purchase price internally funded within the period.
Source: Second-quarter 2026 Form 10-Q, cash-flow statement, Note 5 capital spending, and operating-expense discussion, pages 5, 12 and 37.
7. Short-term refinancing matters more than the debt labels suggest
Bank facilities support liquidity, but some debt classified as long-term must be renewed frequently. Financing debt increased $8.140 billion to $26.558 billion. Subtracting cash gives calculated net debt of $22.210 billion, up from $13.803 billion. This measure excludes operating leases.
The balance sheet shows only $1.411 billion of current debt. However, $4.703 billion of euro commercial paper—short-term borrowing notes—was classified as long-term because Danaher intended and had the supported ability to refinance it beyond one year. Its average remaining maturity was only 79 days. The long-term classification therefore does not show how frequently Danaher must renew these notes or draw on a backup source.
Danaher had an undrawn $5.0 billion revolving bank facility expiring in August 2028 and another undrawn $5.0 billion facility expiring in April 2027. They provide commercial-paper support and borrowing flexibility. Their capacity cannot be counted once as support for outstanding paper and again as wholly independent spending money. The shorter facility permits a conditional one-year extension of outstanding loans for a 0.50% conversion fee. Danaher reported compliance with all debt covenants, including the shorter facility’s contract-defined leverage ceiling of 0.65 to 1.00.
Scheduled note maturities also deserve attention. The debt table lists €800 million due in September 2026, CHF250 million in April 2027, ¥30.8 billion in May 2027 and €600 million in June 2027. These obligations sit alongside recurring commercial-paper refinancing. The company said it expected to meet maturities with cash, new paper, bank facilities or other debt issuance.
Source: Second-quarter 2026 Form 10-Q, Note 10, pages 16–19, and cash requirements, pages 41–42.
Masimo financing also spread repayments over longer periods. New euro notes totaled €3.0 billion, with maturities from 2028 to 2038; the fixed-rate tranches carry coupons of 3.25%, 3.625% and 4.00%, alongside a floating-rate tranche. New Swiss-franc notes totaled CHF2.383 billion, mature from 2031 to 2056 and carry rates from 1.65% to 2.51%. The maturity spread reduces dependence on one refinancing date, although foreign-currency borrowing introduces translation and hedging considerations.
Commercial paper carried a weighted-average annual rate of 2.5%. Holding its $4.703 billion balance constant, a one-percentage-point increase would add approximately $47 million of annual interest before tax and any offsets. This is a sensitivity calculation, not a forecast. It shows how reducing commercial-paper borrowing would limit the cash cost of a rise in short-term interest rates.
Actual first-half interest expense was $170 million and cash interest paid was $136 million; payment dates and accounting recognition differ. Management assumed about $115 million of third-quarter net interest expense at June 26 exchange rates and unchanged commercial-paper balances. That compares with actual second-quarter net interest expense of $46 million and makes the post-acquisition funding burden more visible.
Sources: Second-quarter 2026 Form 10-Q, pages 5, 16–19 and 38; July 21 earnings release, financing assumptions, PDF page 5.
Lease payments are another cash commitment. Operating lease liabilities remained approximately $1.3 billion at June 26. The earlier December 2025 maturity schedule listed $239 million payable in 2026 and $201 million in 2027; those are year-end contractual amounts, not an updated remaining-payment schedule after acquiring Masimo. Approximately $3.1 billion of the June cash balance was outside the United States, with most foreign cash potentially repatriable but some subject to restrictions or distribution taxes. Liquidity is substantial, but it requires active management across maturities and jurisdictions.
Sources: Second-quarter 2026 Form 10-Q, Note 1 and cash requirements; 2025 Annual Report, Note 9, printed page 83.
8. Repurchases reduced shares, while currency movements limited equity growth
Danaher returned cash and reduced its share count despite the acquisition borrowing. The company repurchased approximately five million shares in the first half. Buying back shares reduces the number over which earnings are divided and can offset shares issued for employee compensation. The filing says repurchased shares remain available for employee compensation or other corporate purposes, and management controls the timing of purchases. These benefits use cash that could otherwise support integration or debt repayment.
Cash repurchases were $894 million. The equity statement recorded $903 million including accrued excise tax, while $27 million of cash excise taxes relating to earlier repurchases appeared separately in other financing activity. Dividends paid were $509 million, compared with $564 million declared. Payment and declaration dates explain why the cash-flow and equity statements use different amounts.
Outstanding shares fell from 706.9 million at year-end to 702.9 million, even though issued shares rose from 886.9 million to 888.2 million through stock-award activity. Repurchased shares remain in treasury; they should not be described as retired. First-half stock-compensation expense was $151 million versus $152 million. It adds back to operating cash because it is noncash when expensed, but issuing shares can spread ownership over more shares.
The diluted quarterly average declined from 719.1 million to 707.6 million. At the earlier share count, the current quarter’s $870 million earnings would produce approximately $1.21 per share rather than the reported $1.23. Repurchases and other share movements therefore helped EPS, but the earnings change was the much larger driver.
Total equity increased only $51 million to $52.592 billion. Retained earnings rose $1.335 billion after earnings and declared dividends. Paid-in capital increased $265 million, including $220 million of stock-award activity and $45 million of acquisition consideration. Treasury stock reduced equity by another $965 million. Other comprehensive losses reduced equity by $588 million, principally currency translation losses of $543 million and cash-flow hedge losses of $46 million, partly offset by $1 million of pension adjustments. Noncontrolling interests added $4 million.
Source: Second-quarter 2026 Form 10-Q, consolidated equity and comprehensive-income statements, pages 3–4; Notes 3 and 13, pages 8–9 and 23–27.
These currency-related equity movements largely reflect translating foreign operations and hedging positions rather than distributing cash. The practical capital-allocation choice remains separate: after financing a major purchase, Danaher can retain more future cash for debt repayment by moderating discretionary repurchases, or continue distributions while relying longer on external funding.
9. The acquisition brings legal obligations as well as new products
Masimo’s strategic fit must be assessed alongside unresolved inherited exposures. The purchase allocation remained preliminary, including its treatment of legal contingencies. These matters can affect future spending and management attention even before a reliable loss estimate is available.
The most prominent potential recovery is Masimo’s $634 million patent verdict against Apple. At the filing cutoff, final judgment was pending. Separately, an April 2026 trade ruling found that Apple’s redesigned watch did not violate the relevant import-exclusion order, and Masimo appealed. These are different proceedings; a damages verdict should not be treated as collected cash or automatically used to offset Danaher’s debt.
Potential outflows include a Department of Justice investigation concerning Rad-G and Rad-97 products, complaints, returns and the Rad-G recall. A supplemental grand-jury subpoena arrived in February 2026. Former Masimo chief executive Joe Kiani also sought severance including the value of 2.7 million Masimo shares and $35 million in cash. Those are claims, not established obligations or Danaher’s estimated loss. Willow’s arbitration included a damages demand of at least $6 million and disputes over technology rights and royalty obligations.
Danaher said it could not reasonably estimate the possible loss or range of loss for the described Masimo proceedings. No numerical litigation deduction is therefore imposed here. The useful conclusion is that integration must preserve product quality, intellectual-property access and operating continuity while these matters proceed.
Danaher’s separate Hawkins securities case had a settlement liability and an offsetting insurance receivable. Preliminary approval was granted in June, and the company did not expect a material effect on earnings or cash flows. Related derivative proceedings remained uncertain. The insurance support is specific to the disclosed settlement, not blanket protection against all litigation.
Source: Second-quarter 2026 Form 10-Q, Note 12, pages 21–23, and Note 2’s preliminary acquisition-accounting discussion.
Tax uncertainty also remains relevant. Gross unrecognized tax benefits were $1.281 billion at December 2025, a historical balance rather than a June update. The current filing reports $21 million of net discrete tax charges in the first half. It also explains that settling the earlier self-insurance tax dispute did not prevent similar IRS proposals for later years. The previously disputed $2.5 billion was taxable income, not a tax bill.
Sources: 2025 Annual Report, Note 7, printed pages 80–81; second-quarter 2026 Form 10-Q, Note 6, page 13.
The filing also reports delivery delays and higher logistics costs linked to Middle East conflict, although no material first-half interruption to operations or supply chains. Tariffs and related refunds had not materially affected the periods presented. Danaher intended to recognize future eligible refunds net of amounts due to customers. Neither potential refunds nor legal recoveries provide a sound substitute for operating cash in evaluating the acquisition’s funding needs.
Source: Second-quarter 2026 Form 10-Q, business outlook and risk factors, pages 30–31 and 42–43.
10. The next improvement must come from deliveries and integration
Danaher has a productive cash-generating base, but the larger business needs more than an easy profit comparison. Life Sciences demand improved, Biotechnology consumables supported growth, and clinical diagnostics expanded outside the respiratory-testing weakness. Those operating gains supported investment and distributions. They did not fund the scale of the Masimo purchase.
Management reported mid-teens second-quarter bioprocessing order growth and forecast core sales growth of 2%–3% for the third quarter and 3%–4% for 2026. Orders support later shipments but are not revenue.
Source: July 21, 2026 earnings release, management commentary and outlook, PDF page 1.
The strongest path forward is concrete. Delivering delayed customer orders would turn existing demand into sales. Better test mix and firmer clinical volumes would help Diagnostics absorb its operating costs. Masimo’s products widen hospital relationships, while integration savings can progressively improve the cash earned from that added revenue. The conditions are successful delivery, continued customer use and realized savings, rather than merely a larger acquired sales base.
Danaher can support the integration period with existing cash generation and committed borrowing capacity. Its expanded financing burden nevertheless makes retaining cash and managing short-term renewals more consequential. The overall business assessment is an improving but uneven operating recovery, combined with a strategically coherent acquisition whose full cash contribution still lies ahead.
Technical calculation and source notes
- Filing identity and periods: Danaher Corporation, CIK 0000313616, Form 10-Q, accession 0000313616-26-000161, filed July 21, 2026. EDGAR acceptance was July 20 at 17:48:38; that timestamp is not the filing date. Current-quarter dates are March 28–June 26, 2026, compared with March 29–June 27, 2025. First-half periods begin January 1 in each year. The balance-sheet comparison is June 26, 2026 versus December 31, 2025.
Source: SEC filing index and Form 10-Q cover and statement contexts.
- XBRL checks: USD facts from the stated accession were checked against the consolidated statements, using actual start/end dates rather than the fiscal-period label alone. Checked tags include
RevenueFromContractWithCustomerExcludingAssessedTax,Assets,LiabilitiesAndStockholdersEquity,StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest,NetIncomeLossandNetCashProvidedByUsedInOperatingActivities. The revenue fact agrees with reported sales; Note 4 says reported revenue includes lease revenue. The cash fact usesCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents; its values match the statement’s cash-and-equivalents totals, with no separate restricted-cash reconciling balance presented. No additional cash balance is inferred from the tag’s broader name.
Source: SEC Danaher company facts, filtered to the specified accession and USD units; Form 10-Q, pages 1–5 and Note 4.
Growth and margins: Growth equals current amount divided by its like-period comparator, minus one. Calculated revenue growth is 5.54% for the quarter and 4.62% for the first half; Danaher’s rounded growth presentation is 5.5% and 4.5%. Operating margin equals operating profit divided by revenue. Selected-item margins use the exact dollar inputs in Section 1. The displayed first-half 21.25% margins differ by less than 0.01 percentage point before rounding. Pro forma revenue growth is $6,511 million divided by $6,307 million, minus one.
Balance-sheet reconciliation: June assets of $92,367 million equal liabilities of $39,775 million plus equity of $52,592 million. December assets of $83,464 million equal liabilities of $30,923 million plus equity of $52,541 million. Debt includes current financing obligations and long-term debt at carrying amount, net of issuance adjustments; net debt subtracts reported cash and excludes operating leases. The increase in borrowing cash proceeds is not identical to the change in debt carrying value because currency and other noncash or issuance-related movements also affect that balance.
Cash and equity checks: Listed noncash additions total $1,567 million in 2026 and $1,926 million in 2025. Working-capital and other operating-balance movements total negative $610 million and negative $798 million, respectively. Thus $1,899 + $1,567 − $610 = $2,856 million of 2026 operating cash. Equity reconciles as $52,541 + $265 − $965 + $1,335 − $588 + $4 = $52,592 million. Free cash flow, share-count effects and interest sensitivity are calculated measures with definitions and inputs given beside the relevant evidence.
This report provides company and accounting analysis for information only. It is not investment advice.